An Aliquoting Strategy for Commercial Gallium-68 Radiopharmaceutical Cold Kits.

Ga colloids), indicating lower process robustness. Aliquoting reduced the theoretical radiopharmaceutical cost per patient dose by 38.6% for gozetotide and 35.7% for edotreotide. After accounting for the 26.0% edotreotide non-conformity rate in a replacement sensitivity analysis, the estimated edotreotide cost reduction remained 19.0%, and total annual savings at our institution were approximately 111,000 €. This kit-specific strategy can improve cold-kit utilization and reduce costs, but requires rigorous in-house validation and quality control.